PolyPid Announces Presentation at the 2022 Military Health System Research Symposium

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced the presentation of Phase 2 clinical and animal study data for D-PLEX100 at the 2022 Military Health System Research Symposium from September 12-15, 2022. The podium presentation will address D-PLEX100's efficacy in reducing surgical site infection rates and drug-resistant bacteria in surgical trauma injuries. This presentation will be led by Noam Emanuel, PhD, Co-Founder and Chief Scientific Officer. D-PLEX100 is currently in Phase 3 trials aimed at preventing surgical site infections.

Positive

• D-PLEX100 shows promise in reducing surgical site infections and drug-resistant bacteria.
• Presentation at a reputable symposium could enhance visibility and credibility in the medical community.
• D-PLEX100 is in Phase 3 trials, indicating progress in development.

Negative

• No specific clinical trial results or data shared could lead to uncertainty regarding effectiveness.
• Dependency on successful trial outcomes for future market viability.

Efficacy Data of D-PLEX₁₀₀ in reduction of Surgical Site Infection in Surgical Trauma Injuries will be Presented During a Podium Presentation

PETACH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data and animal study data for D-PLEX₁₀₀ in surgical trauma injuries will be highlighted in a podium presentation at the 2022 Military Health System Research Symposium (MHSRS) being held on September 12-15, 2022, at the Gaylord Palms Resort and Convention Center, Kissimmee, Florida.

The 2022 Military Health System Research Symposium:

Title:	D-PLEX100, a doxycycline releasing antimicrobial product for surgical site wounds, reduces surgical site infection rates and drug resistant-bacteria in surgical trauma injuries.
Presenter:	Noam Emanuel, PhD, Co-Founder and Chief Scientific Officer, PolyPid.
Date:	Monday, September 12, 2022

The abstract will be available on www.polypid.com/publications/ following the presentation.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts: 
PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

Media Contact:
Nechama Feuerstein
551-444-0784
Nechama.Feuerstein@finnpartners.com 

FAQ

What is D-PLEX100 and its significance for PYPD?

D-PLEX100 is a doxycycline-releasing antimicrobial product aimed at reducing surgical site infections, currently in Phase 3 trials.

When is the presentation for D-PLEX100 taking place?

The presentation will be held at the 2022 Military Health System Research Symposium from September 12-15, 2022.

What company is behind the D-PLEX100 product?

The product is developed by PolyPid Ltd., which trades under the ticker symbol PYPD.

Where can I find more information about the D-PLEX100 presentation?

Additional information will be available on the company's official website following the presentation.

What are the current clinical trial phases for D-PLEX100?

D-PLEX100 is currently in Phase 3 clinical trials for preventing surgical site infections.